SoFi stock falls after announcing $1.5B public offering of common stock
Investing.com - Raymond James has raised its price target on Inflarx NV (NASDAQ:IFRX) to $9.00 from $2.00 while maintaining an Outperform rating following the company’s third-quarter 2025 earnings report. The news has contributed to IFRX’s impressive 24.41% gain over the past week, according to InvestingPro data.
The significant price target increase was primarily driven by strong early efficacy and safety data from Inflarx’s oral C5aR inhibitor (INF904) in hidradenitis suppurativa (HS) patients as part of a Phase 2a autoimmune disease basket study.
For patients receiving the 120mg BID dosage, the HiSCR50 response rate increased from 38% at Week 4 to 63% at Week 8 after drug discontinuation, while draining tunnel reduction was -2.2 at Week 4 from a baseline mean of 3.3, and pain score response reached 75% compared to less than 50% in competitor Phase 3 studies.
The chronic spontaneous urticaria (CSU) results were less definitive due to lack of dose-dependent signal, though the UAS7 for the 60mg BID dose was described as being in a competitive range. With a current ratio of 4.1, InvestingPro data shows Inflarx’s liquid assets comfortably exceed short-term obligations, though the company continues to burn through cash with an EBITDA of -$61.81 million in the last twelve months.
Raymond James noted that Inflarx has "come full circle back to HS" after previous focus shifts to COVID-19/ARDS and pyoderma gangrenosum, viewing the current dataset as a strong foundation for potentially successful programs in HS and other complement-driven autoimmune diseases. With a market cap of $107 million and analyst price targets ranging from $1.97 to $9.85, investors will be watching closely for Inflarx’s next earnings report on November 11. InvestingPro offers 12 additional tips on Inflarx’s financial health, valuation metrics and growth prospects to help investors make more informed decisions about this clinical-stage biotech company.
In other recent news, InflaRx has reported positive Phase 2a data for its oral C5aR inhibitor, INF904, targeting hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The study demonstrated promising efficacy, with notable improvements in HS patients, including reductions in abscesses and pain over a four-week treatment period. Additionally, InflaRx announced it will release its third quarter 2025 financial results and detailed trial data on November 10, 2025, accompanied by a webcast and conference call. The company has also regained compliance with Nasdaq’s minimum bid price requirement, maintaining a closing bid price of at least $1.00 for ten consecutive business days. Furthermore, H.C. Wainwright has assumed coverage of InflaRx with a Buy rating and a $6.00 price target, citing the potential of its lead assets, vilobelimab and INF904. These developments reflect a series of positive updates for InflaRx, capturing investor interest and analyst attention.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.